Related Experiment Video
Updated: May 17, 2026
06:21
Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
Published on: May 10, 2024
Warfarin pharmacogenetics: does more accurate dosing benefit patients?
1Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, Missouri, USA. eby@wustl.edu
Seminars in Thrombosis and Hemostasis
|October 11, 2012
Summary
Pharmacogenetic-guided warfarin dosing shows promise but requires more evidence. Genetic factors influence warfarin response, improving initial dose accuracy, but routine clinical benefits and cost-effectiveness are still under investigation.
Area of Science:
- Pharmacology
- Genetics
- Internal Medicine
Background:
- Warfarin dosing is complex, with significant variability.
- Cytochrome P 450 2C9 (CYP2C9) and vitamin K reductase complex 1 (VKORC1) gene single nucleotide polymorphisms (SNPs) influence warfarin metabolism and sensitivity.
- These genetic factors explain about 30% of dosing variability in certain populations.
Purpose of the Study:
- To evaluate the current status and future directions of pharmacogenetic-guided warfarin dosing.
- To assess the impact of genetic information on initial warfarin dose accuracy.
- To determine the clinical utility and cost-effectiveness of routine warfarin pharmacogenetics.
Main Methods:
- Review of a decade of clinical investigation into warfarin pharmacogenetics.
- Analysis of the contribution of CYP2C9 and VKORC1 SNPs to warfarin dosing variability.
- Consideration of ongoing international randomized clinical trials.
Main Results:
- Pharmacogenetic information, alongside clinical factors like age and body size, improves initial warfarin dosing accuracy.
- Currently, insufficient evidence exists regarding the clinical benefits and cost-effectiveness of routine warfarin pharmacogenetics.
Conclusions:
- Pharmacogenetic-guided warfarin dosing is at a critical juncture.
- Further evidence from ongoing trials is needed to establish the role of warfarin pharmacogenetics in personalized medicine.
Related Concept Videos
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...